SK11892000A3 - Zlúčeniny a ich použitie ako pozitívnych modulátorov ampa receptora - Google Patents

Zlúčeniny a ich použitie ako pozitívnych modulátorov ampa receptora Download PDF

Info

Publication number: SK11892000A3
Authority: SK; Slovakia
Prior art keywords: alkyl; aryl; benzyl; dioxide; cycloalkyl
Prior art date: 1998-02-18

Application number

SK1189-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Mogens Larsen

Thomas Varming

Claus Mathiesen

Jorgen Schell-Kr�Ger

Gunnar M. Olsen

Tina Holm Johansen

Elsebet Ostergaard Nielsen

Alex Haahr Gouliaev

Original Assignee

Neurosearch A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-18

Filing date

1999-02-18

Publication date

2001-02-12

1999-02-18 Application filed by Neurosearch A/S filed Critical Neurosearch A/S

2001-02-12 Publication of SK11892000A3 publication Critical patent/SK11892000A3/sk

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 207
102000003678 AMPA Receptors Human genes 0.000 title claims abstract description 23
108090000078 AMPA Receptors Proteins 0.000 title claims abstract description 23
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 165
239000001257 hydrogen Substances 0.000 claims abstract description 163
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 83
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 71
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 69
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 15
125000000217 alkyl group Chemical group 0.000 claims description 553
125000003118 aryl group Chemical group 0.000 claims description 275
238000000034 method Methods 0.000 claims description 267
125000000753 cycloalkyl group Chemical group 0.000 claims description 206
125000003545 alkoxy group Chemical group 0.000 claims description 177
-1 atom hydrogen Chemical class 0.000 claims description 176
229910052736 halogen Inorganic materials 0.000 claims description 174
150000002367 halogens Chemical class 0.000 claims description 174
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 172
125000000623 heterocyclic group Chemical group 0.000 claims description 136
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 130
125000001424 substituent group Chemical group 0.000 claims description 113
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 109
125000000304 alkynyl group Chemical group 0.000 claims description 94
125000003342 alkenyl group Chemical group 0.000 claims description 92
125000001188 haloalkyl group Chemical group 0.000 claims description 67
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 60
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 58
125000004149 thio group Chemical group *S* 0.000 claims description 53
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 50
239000000460 chlorine Substances 0.000 claims description 46
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 37
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 34
125000004966 cyanoalkyl group Chemical group 0.000 claims description 31
125000004438 haloalkoxy group Chemical group 0.000 claims description 30
PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims description 26
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
208000035475 disorder Diseases 0.000 claims description 25
125000004429 atom Chemical group 0.000 claims description 24
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 23
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 23
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 23
125000005842 heteroatom Chemical group 0.000 claims description 23
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 22
125000004971 nitroalkyl group Chemical group 0.000 claims description 22
201000010099 disease Diseases 0.000 claims description 21
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 20
238000002360 preparation method Methods 0.000 claims description 19
150000003839 salts Chemical class 0.000 claims description 19
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 17
125000004093 cyano group Chemical group *C#N 0.000 claims description 16
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 16
125000002837 carbocyclic group Chemical group 0.000 claims description 15
238000011282 treatment Methods 0.000 claims description 15
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 14
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 14
208000024827 Alzheimer disease Diseases 0.000 claims description 13
125000003277 amino group Chemical group 0.000 claims description 13
229910052794 bromium Inorganic materials 0.000 claims description 13
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 13
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 12
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 11
208000026139 Memory disease Diseases 0.000 claims description 11
239000008194 pharmaceutical composition Substances 0.000 claims description 11
LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims description 10
125000003282 alkyl amino group Chemical group 0.000 claims description 10
125000004414 alkyl thio group Chemical group 0.000 claims description 10
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 10
229910052801 chlorine Inorganic materials 0.000 claims description 10
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 9
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 claims description 8
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical group C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims description 8
125000001246 bromo group Chemical group Br* 0.000 claims description 8
230000015654 memory Effects 0.000 claims description 8
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
210000003169 central nervous system Anatomy 0.000 claims description 7
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
230000006735 deficit Effects 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
VBKFECXATSSIIS-UHFFFAOYSA-N 3-cyclohexyl-2-methyl-7-morpholin-4-ylsulfonyl-3,4-dihydro-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=C2S(=O)(=O)N(C)C(C3CCCCC3)NC2=CC=C1S(=O)(=O)N1CCOCC1 VBKFECXATSSIIS-UHFFFAOYSA-N 0.000 claims description 6
LNVPUDKWUIASGN-UHFFFAOYSA-N 3-cyclohexyl-3,4,8,9-tetrahydro-2h-[1,4]dioxino[2,3-h][1,2,4]benzothiadiazine 1,1-dioxide Chemical compound N1C2=CC=C3OCCOC3=C2S(=O)(=O)NC1C1CCCCC1 LNVPUDKWUIASGN-UHFFFAOYSA-N 0.000 claims description 6
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 6
125000002252 acyl group Chemical group 0.000 claims description 6
229910052731 fluorine Inorganic materials 0.000 claims description 6
229910052740 iodine Inorganic materials 0.000 claims description 6
201000003723 learning disability Diseases 0.000 claims description 6
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
QDOQLKXQYLZYEA-UHFFFAOYSA-N (3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazin-8-yl)methanol Chemical compound N1S(=O)(=O)C=2C(CO)=CC=CC=2NC1C1CCCCC1 QDOQLKXQYLZYEA-UHFFFAOYSA-N 0.000 claims description 5
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 5
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 5
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 5
WUMDYVDFUYYKMZ-UHFFFAOYSA-N 3-cyclohexyl-3,4,7,8-tetrahydro-2h-[1,4]dioxino[2,3-g][1,2,4]benzothiadiazine 1,1-dioxide Chemical compound N1C2=CC=3OCCOC=3C=C2S(=O)(=O)NC1C1CCCCC1 WUMDYVDFUYYKMZ-UHFFFAOYSA-N 0.000 claims description 5
125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 5
208000000044 Amnesia Diseases 0.000 claims description 5
208000020358 Learning disease Diseases 0.000 claims description 5
URCISWPLBRCAJO-UHFFFAOYSA-N S(=O)(=O)=C1NS(C2=C(N1)C=CC=C2)(=O)=O Chemical compound S(=O)(=O)=C1NS(C2=C(N1)C=CC=C2)(=O)=O URCISWPLBRCAJO-UHFFFAOYSA-N 0.000 claims description 5
206010039966 Senile dementia Diseases 0.000 claims description 5
208000006011 Stroke Diseases 0.000 claims description 5
125000001309 chloro group Chemical group Cl* 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
230000006984 memory degeneration Effects 0.000 claims description 5
208000023060 memory loss Diseases 0.000 claims description 5
CASOHOKYBJSFPE-UHFFFAOYSA-N n-(3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazin-7-yl)acetamide Chemical compound N1S(=O)(=O)C2=CC(NC(=O)C)=CC=C2NC1C1CCCCC1 CASOHOKYBJSFPE-UHFFFAOYSA-N 0.000 claims description 5
201000000980 schizophrenia Diseases 0.000 claims description 5
125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 4
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 4
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 4
GCKKMVSMOFCWDO-UHFFFAOYSA-N 3-cyclohexyl-8-pyridin-2-yl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=12S(=O)(=O)NC(C3CCCCC3)NC2=CC=CC=1C1=CC=CC=N1 GCKKMVSMOFCWDO-UHFFFAOYSA-N 0.000 claims description 4
LOCXCZBQYNVQCD-UHFFFAOYSA-N 3-cyclopentyl-7-piperidin-1-ylsulfonyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2NC(C3CCCC3)NS(=O)(=O)C2=CC=1S(=O)(=O)N1CCCCC1 LOCXCZBQYNVQCD-UHFFFAOYSA-N 0.000 claims description 4
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims description 4
206010001605 Alcohol poisoning Diseases 0.000 claims description 4
206010003805 Autism Diseases 0.000 claims description 4
208000020706 Autistic disease Diseases 0.000 claims description 4
201000006474 Brain Ischemia Diseases 0.000 claims description 4
241001465754 Metazoa Species 0.000 claims description 4
208000028017 Psychotic disease Diseases 0.000 claims description 4
201000001880 Sexual dysfunction Diseases 0.000 claims description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
230000000747 cardiac effect Effects 0.000 claims description 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
206010015037 epilepsy Diseases 0.000 claims description 4
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
208000014674 injury Diseases 0.000 claims description 4
208000015122 neurodegenerative disease Diseases 0.000 claims description 4
239000002581 neurotoxin Substances 0.000 claims description 4
125000005574 norbornylene group Chemical group 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
231100000872 sexual dysfunction Toxicity 0.000 claims description 4
201000009032 substance abuse Diseases 0.000 claims description 4
231100000736 substance abuse Toxicity 0.000 claims description 4
208000011117 substance-related disease Diseases 0.000 claims description 4
229940124530 sulfonamide Drugs 0.000 claims description 4
238000001356 surgical procedure Methods 0.000 claims description 4
230000008733 trauma Effects 0.000 claims description 4
ZRRASWJMRDYRFA-UHFFFAOYSA-N 1-(3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazin-7-yl)ethanol Chemical compound N1S(=O)(=O)C2=CC(C(O)C)=CC=C2NC1C1CCCCC1 ZRRASWJMRDYRFA-UHFFFAOYSA-N 0.000 claims description 3
JURGPCFAAKMAIA-UHFFFAOYSA-N 2-cyclohexyl-1,2,3,4-tetrahydroquinazoline-6-sulfonamide Chemical compound N1CC2=CC(S(=O)(=O)N)=CC=C2NC1C1CCCCC1 JURGPCFAAKMAIA-UHFFFAOYSA-N 0.000 claims description 3
CCCLGUCOGQADHQ-UHFFFAOYSA-N 2-ethyl-2-methyl-3h-1,3-benzoxazin-4-one Chemical compound C1=CC=C2OC(CC)(C)NC(=O)C2=C1 CCCLGUCOGQADHQ-UHFFFAOYSA-N 0.000 claims description 3
MOFJSTXFUSYCDO-UHFFFAOYSA-N 2-methyl-2,3-dihydro-1,3-benzoxazin-4-one Chemical compound C1=CC=C2OC(C)NC(=O)C2=C1 MOFJSTXFUSYCDO-UHFFFAOYSA-N 0.000 claims description 3
BIVGFFFLVZMILM-UHFFFAOYSA-N 2-phenyl-2,3-dihydro-1h-quinazolin-4-one Chemical compound N1C2=CC=CC=C2C(=O)NC1C1=CC=CC=C1 BIVGFFFLVZMILM-UHFFFAOYSA-N 0.000 claims description 3
ZQGCBOWEEAHZJP-UHFFFAOYSA-N 3-(2-methylpropyl)-8-piperidin-1-ylsulfonyl-2,3,4,5-tetrahydro-1$l^{6},2,5-benzothiadiazepine 1,1-dioxide Chemical compound C1=C2S(=O)(=O)NC(CC(C)C)CNC2=CC=C1S(=O)(=O)N1CCCCC1 ZQGCBOWEEAHZJP-UHFFFAOYSA-N 0.000 claims description 3
ISRRWUNTXIBXAA-UHFFFAOYSA-N 3-cyclohexyl-6-(2-methoxyphenyl)-7-methyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound COC1=CC=CC=C1C(C(=C1)C)=CC2=C1S(=O)(=O)NC(C1CCCCC1)N2 ISRRWUNTXIBXAA-UHFFFAOYSA-N 0.000 claims description 3
VMEPVEFVUCYDSN-UHFFFAOYSA-N 3-cyclohexyl-6-pyridin-3-yl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2S(=O)(=O)NC(C3CCCCC3)NC2=CC=1C1=CC=CN=C1 VMEPVEFVUCYDSN-UHFFFAOYSA-N 0.000 claims description 3
ZJYBPAKREINUPO-UHFFFAOYSA-N 3-cyclohexyl-7-(2-methoxyphenyl)-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound COC1=CC=CC=C1C1=CC=C(NC(NS2(=O)=O)C3CCCCC3)C2=C1 ZJYBPAKREINUPO-UHFFFAOYSA-N 0.000 claims description 3
OXJDOMHSJFVGDD-UHFFFAOYSA-N 3-cyclohexyl-7-(4-methylpiperazin-1-yl)sulfonyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(NC(NS2(=O)=O)C3CCCCC3)C2=C1 OXJDOMHSJFVGDD-UHFFFAOYSA-N 0.000 claims description 3
DJSOQLXTYIGTAN-UHFFFAOYSA-N 3-cyclohexyl-7-(4-methylsulfonylpiperazin-1-yl)sulfonyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1CN(S(=O)(=O)C)CCN1S(=O)(=O)C1=CC=C(NC(NS2(=O)=O)C3CCCCC3)C2=C1 DJSOQLXTYIGTAN-UHFFFAOYSA-N 0.000 claims description 3
PERVUQCEACNMMX-UHFFFAOYSA-N 3-cyclohexyl-7-pyrrolidin-1-ylsulfonyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2NC(C3CCCCC3)NS(=O)(=O)C2=CC=1S(=O)(=O)N1CCCC1 PERVUQCEACNMMX-UHFFFAOYSA-N 0.000 claims description 3
XCDAUCDJYPFMPQ-UHFFFAOYSA-N 4-oxo-2-(trifluoromethyl)-1h-quinazoline-6-sulfonic acid Chemical compound N1=C(C(F)(F)F)NC(=O)C2=CC(S(=O)(=O)O)=CC=C21 XCDAUCDJYPFMPQ-UHFFFAOYSA-N 0.000 claims description 3
PBSYDJWXTZFDNB-UHFFFAOYSA-N 5,7-dibromo-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound N1=CNS(=O)(=O)C2=CC(Br)=CC(Br)=C21 PBSYDJWXTZFDNB-UHFFFAOYSA-N 0.000 claims description 3
230000032683 aging Effects 0.000 claims description 3
125000004445 cyclohaloalkyl Chemical group 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
FZICIDCLEHENHI-UHFFFAOYSA-N n-[1-(3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazin-7-yl)ethylidene]hydroxylamine Chemical compound N1S(=O)(=O)C2=CC(C(=NO)C)=CC=C2NC1C1CCCCC1 FZICIDCLEHENHI-UHFFFAOYSA-N 0.000 claims description 3
PSOPMMVKRIPMTJ-UHFFFAOYSA-N 1-(sulfonylmethyl)piperazine Chemical compound O=S(=O)=CN1CCNCC1 PSOPMMVKRIPMTJ-UHFFFAOYSA-N 0.000 claims description 2
XUQWBBUOVQYUAZ-UHFFFAOYSA-N 3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-carbonitrile Chemical compound N1C2=CC=C(C#N)C=C2S(=O)(=O)NC1C1CCCCC1 XUQWBBUOVQYUAZ-UHFFFAOYSA-N 0.000 claims description 2
RHFPLXHXCXCOMP-UHFFFAOYSA-N 3-cyclohexyl-6-methyl-7-morpholin-4-ylsulfonyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound CC1=CC=2NC(C3CCCCC3)NS(=O)(=O)C=2C=C1S(=O)(=O)N1CCOCC1 RHFPLXHXCXCOMP-UHFFFAOYSA-N 0.000 claims description 2
LTTNPGLVTMWWQN-UHFFFAOYSA-N 3-cyclohexyl-7-(1-methylimidazol-2-yl)-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound CN1C=CN=C1C1=CC=C(NC(NS2(=O)=O)C3CCCCC3)C2=C1 LTTNPGLVTMWWQN-UHFFFAOYSA-N 0.000 claims description 2
IOTOZEFUYSZNDX-UHFFFAOYSA-N 3-cyclohexyl-7-(2-nitrophenyl)-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound [O-][N+](=O)C1=CC=CC=C1C1=CC=C(NC(NS2(=O)=O)C3CCCCC3)C2=C1 IOTOZEFUYSZNDX-UHFFFAOYSA-N 0.000 claims description 2
QWTNOOUBLHKKDP-UHFFFAOYSA-N 3-cyclohexyl-7-morpholin-4-ylsulfonyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2NC(C3CCCCC3)NS(=O)(=O)C2=CC=1S(=O)(=O)N1CCOCC1 QWTNOOUBLHKKDP-UHFFFAOYSA-N 0.000 claims description 2
KGNRLPYIJPANAS-UHFFFAOYSA-N 3-cyclohexyl-8-(2-methoxyphenyl)-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound COC1=CC=CC=C1C1=CC=CC2=C1S(=O)(=O)NC(C1CCCCC1)N2 KGNRLPYIJPANAS-UHFFFAOYSA-N 0.000 claims description 2
SJXMJUXZVDLBTM-UHFFFAOYSA-N 3-cyclohexyl-8-methyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound N1S(=O)(=O)C=2C(C)=CC=CC=2NC1C1CCCCC1 SJXMJUXZVDLBTM-UHFFFAOYSA-N 0.000 claims description 2
OFRSZWPEVPVADE-UHFFFAOYSA-N 3-cyclohexyl-n,n-diethyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1S(=O)(=O)C2=CC(S(=O)(=O)N(CC)CC)=CC=C2NC1C1CCCCC1 OFRSZWPEVPVADE-UHFFFAOYSA-N 0.000 claims description 2
GXICUQFGNSKOGE-UHFFFAOYSA-N 3-cyclopropyl-7-piperidin-1-ylsulfonyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2NC(C3CC3)NS(=O)(=O)C2=CC=1S(=O)(=O)N1CCCCC1 GXICUQFGNSKOGE-UHFFFAOYSA-N 0.000 claims description 2
KGKLCYCKFOODPJ-UHFFFAOYSA-N 7-(benzenesulfonyl)-3-cyclohexyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2NC(C3CCCCC3)NS(=O)(=O)C2=CC=1S(=O)(=O)C1=CC=CC=C1 KGKLCYCKFOODPJ-UHFFFAOYSA-N 0.000 claims description 2
OMTZRUHDZJHIHA-UHFFFAOYSA-N 7-piperidin-1-ylsulfonyl-3-propan-2-yl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=C2S(=O)(=O)NC(C(C)C)NC2=CC=C1S(=O)(=O)N1CCCCC1 OMTZRUHDZJHIHA-UHFFFAOYSA-N 0.000 claims description 2
DUSPWCCMTHFRRY-UHFFFAOYSA-N O=S(=O)NC1CCCCC1 Chemical compound O=S(=O)NC1CCCCC1 DUSPWCCMTHFRRY-UHFFFAOYSA-N 0.000 claims description 2
150000001408 amides Chemical class 0.000 claims description 2
UZXKCEIWIQJPNG-UHFFFAOYSA-N ethyl 3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-carboxylate Chemical compound N1S(=O)(=O)C2=CC(C(=O)OCC)=CC=C2NC1C1CCCCC1 UZXKCEIWIQJPNG-UHFFFAOYSA-N 0.000 claims description 2
BUDNHGGBRYMVAA-UHFFFAOYSA-N n,n-dimethyl-1,1-dioxo-3-(trifluoromethyl)-4h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1=C(C(F)(F)F)NS(=O)(=O)C2=CC(S(=O)(=O)N(C)C)=CC=C21 BUDNHGGBRYMVAA-UHFFFAOYSA-N 0.000 claims description 2
BFWRYRCBVRTVBX-UHFFFAOYSA-N n-(dimethylsulfamoyl)benzenesulfonamide Chemical compound CN(C)S(=O)(=O)NS(=O)(=O)C1=CC=CC=C1 BFWRYRCBVRTVBX-UHFFFAOYSA-N 0.000 claims description 2
ATIOZSZEDIGMIS-UHFFFAOYSA-N n-sulfonylbenzenesulfonamide Chemical compound O=S(=O)=NS(=O)(=O)C1=CC=CC=C1 ATIOZSZEDIGMIS-UHFFFAOYSA-N 0.000 claims description 2
125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims description 2
150000008349 1,2,4-benzothiadiazines Chemical class 0.000 claims 2
SSILWQXUCHXMTP-UHFFFAOYSA-N 2-cyclohexyl-2,3-dihydro-1h-quinazolin-4-one Chemical compound N1C2=CC=CC=C2C(=O)NC1C1CCCCC1 SSILWQXUCHXMTP-UHFFFAOYSA-N 0.000 claims 1
DHCPORJPDBADEG-UHFFFAOYSA-N 3,4,4a,5-tetrahydro-2H-1lambda6,2,4-benzothiadiazine 1,1-dioxide Chemical compound S1(NCNC2C1=CC=CC2)(=O)=O DHCPORJPDBADEG-UHFFFAOYSA-N 0.000 claims 1
WZECQUDNNKHKQK-UHFFFAOYSA-N 3-cyclohexyl-7-(2,4-dimethoxyphenyl)-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound COC1=CC(OC)=CC=C1C1=CC=C(NC(NS2(=O)=O)C3CCCCC3)C2=C1 WZECQUDNNKHKQK-UHFFFAOYSA-N 0.000 claims 1
YIAWKBKPGWWSLY-UHFFFAOYSA-N 3-cyclohexyl-8-(3-methoxyphenyl)-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound COC1=CC=CC(C=2C=3S(=O)(=O)NC(NC=3C=CC=2)C2CCCCC2)=C1 YIAWKBKPGWWSLY-UHFFFAOYSA-N 0.000 claims 1
MAKFSUYZYPTPCS-UHFFFAOYSA-N 3-cyclohexyl-n-methyl-1,1-dioxo-n-phenyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C=1C=C2NC(C3CCCCC3)NS(=O)(=O)C2=CC=1S(=O)(=O)N(C)C1=CC=CC=C1 MAKFSUYZYPTPCS-UHFFFAOYSA-N 0.000 claims 1
YYPWDMFWDGAUPK-UHFFFAOYSA-N 4-oxo-2-(trifluoromethyl)-1h-quinazoline-6-sulfonamide Chemical compound N1=C(C(F)(F)F)NC(=O)C2=CC(S(=O)(=O)N)=CC=C21 YYPWDMFWDGAUPK-UHFFFAOYSA-N 0.000 claims 1
125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
WZWQJRQCWCFUTM-UHFFFAOYSA-N morpholine-4-sulfonamide Chemical compound NS(=O)(=O)N1CCOCC1 WZWQJRQCWCFUTM-UHFFFAOYSA-N 0.000 claims 1
WWEMWQKCUKUJHS-UHFFFAOYSA-N n,n,3-trimethyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(S(=O)(=O)N(C)C)C=C2S(=O)(=O)NC(C)NC2=C1 WWEMWQKCUKUJHS-UHFFFAOYSA-N 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 124
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 98
239000011541 reaction mixture Substances 0.000 description 94
KVFDZFBHBWTVID-UHFFFAOYSA-N cyclohexanecarbaldehyde Chemical compound O=CC1CCCCC1 KVFDZFBHBWTVID-UHFFFAOYSA-N 0.000 description 90
239000000243 solution Substances 0.000 description 86
239000000203 mixture Substances 0.000 description 77
UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 70
150000002431 hydrogen Chemical class 0.000 description 66
235000019439 ethyl acetate Nutrition 0.000 description 62
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 62
239000000047 product Substances 0.000 description 62
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 54
238000002844 melting Methods 0.000 description 53
230000008018 melting Effects 0.000 description 53
150000001412 amines Chemical class 0.000 description 51
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
239000007858 starting material Substances 0.000 description 45
YAZSBRQTAHVVGE-UHFFFAOYSA-N 2-aminobenzenesulfonamide Chemical class NC1=CC=CC=C1S(N)(=O)=O YAZSBRQTAHVVGE-UHFFFAOYSA-N 0.000 description 42
239000011734 sodium Substances 0.000 description 42
230000000694 effects Effects 0.000 description 39
238000010626 work up procedure Methods 0.000 description 39
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
239000007787 solid Substances 0.000 description 33
UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 31
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 29
238000004440 column chromatography Methods 0.000 description 26
239000002904 solvent Substances 0.000 description 26
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
239000004480 active ingredient Substances 0.000 description 22
239000000843 powder Substances 0.000 description 22
IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 21
229940125807 compound 37 Drugs 0.000 description 21
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 20
230000004044 response Effects 0.000 description 20
239000002244 precipitate Substances 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 17
238000002474 experimental method Methods 0.000 description 17
229920000728 polyester Polymers 0.000 description 17
DJMOXMNDXFFONV-UHFFFAOYSA-N 1,3-dimethyl-7-[2-(n-methylanilino)ethyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCN(C)C1=CC=CC=C1 DJMOXMNDXFFONV-UHFFFAOYSA-N 0.000 description 16
TZPOFKNGJJYOPZ-UHFFFAOYSA-N 2-amino-5-iodobenzenesulfonamide Chemical compound NC1=CC=C(I)C=C1S(N)(=O)=O TZPOFKNGJJYOPZ-UHFFFAOYSA-N 0.000 description 15
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 15
RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 15
238000001914 filtration Methods 0.000 description 15
102000005962 receptors Human genes 0.000 description 15
108020003175 receptors Proteins 0.000 description 15
229920006395 saturated elastomer Polymers 0.000 description 15
239000000725 suspension Substances 0.000 description 15
PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 14
239000000741 silica gel Substances 0.000 description 14
229910002027 silica gel Inorganic materials 0.000 description 14
238000003756 stirring Methods 0.000 description 14
239000002775 capsule Substances 0.000 description 13
239000000706 filtrate Substances 0.000 description 13
238000012360 testing method Methods 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 11
238000001816 cooling Methods 0.000 description 11
238000003818 flash chromatography Methods 0.000 description 11
238000009472 formulation Methods 0.000 description 11
229960003692 gamma aminobutyric acid Drugs 0.000 description 11
210000002569 neuron Anatomy 0.000 description 11
239000011780 sodium chloride Substances 0.000 description 11
CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 10
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 10
239000012044 organic layer Substances 0.000 description 10
239000003826 tablet Substances 0.000 description 10
FPXADHOTCMFHQQ-UHFFFAOYSA-N 3-cyclopentyl-6-methyl-7-piperidin-1-ylsulfonyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound CC1=CC=2NC(C3CCCC3)NS(=O)(=O)C=2C=C1S(=O)(=O)N1CCCCC1 FPXADHOTCMFHQQ-UHFFFAOYSA-N 0.000 description 9
IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
239000002253 acid Substances 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
239000013078 crystal Substances 0.000 description 9
239000002552 dosage form Substances 0.000 description 9
239000003480 eluent Substances 0.000 description 9
210000001320 hippocampus Anatomy 0.000 description 9
DQNCVHIKQIPEIA-UHFFFAOYSA-N 2-amino-3,5-dibromobenzenesulfonamide Chemical compound NC1=C(Br)C=C(Br)C=C1S(N)(=O)=O DQNCVHIKQIPEIA-UHFFFAOYSA-N 0.000 description 8
229930195714 L-glutamate Natural products 0.000 description 8
239000007864 aqueous solution Substances 0.000 description 8
AJIBZRIAUXVGQJ-UHFFFAOYSA-N bicyclo[2.2.1]hept-2-ene-5-carbaldehyde Chemical compound C1C2C(C=O)CC1C=C2 AJIBZRIAUXVGQJ-UHFFFAOYSA-N 0.000 description 8
239000000872 buffer Substances 0.000 description 8
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 8
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
239000012043 crude product Substances 0.000 description 7
238000001962 electrophoresis Methods 0.000 description 7
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 7
239000002609 medium Substances 0.000 description 7
239000008188 pellet Substances 0.000 description 7
238000001953 recrystallisation Methods 0.000 description 7
239000000126 substance Substances 0.000 description 7
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
239000008346 aqueous phase Substances 0.000 description 6
239000002585 base Substances 0.000 description 6
230000027455 binding Effects 0.000 description 6
238000009739 binding Methods 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000005457 ice water Substances 0.000 description 6
230000002154 ionophoretic effect Effects 0.000 description 6
230000001537 neural effect Effects 0.000 description 6
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 6
229920002401 polyacrylamide Polymers 0.000 description 6
238000010992 reflux Methods 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
TUHHVUXXOPCMLZ-UHFFFAOYSA-N 2-amino-4-bromobenzenesulfonamide Chemical compound NC1=CC(Br)=CC=C1S(N)(=O)=O TUHHVUXXOPCMLZ-UHFFFAOYSA-N 0.000 description 5
NECSZWFYSDDJSW-UHFFFAOYSA-N 2-amino-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C(N)=C1 NECSZWFYSDDJSW-UHFFFAOYSA-N 0.000 description 5
XSVCDKNLLZPUHQ-UHFFFAOYSA-N 3-(1-adamantyl)-5,7-dibromo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1C(C2)CC(C3)CC2CC13C1NC2=C(Br)C=C(Br)C=C2S(=O)(=O)N1 XSVCDKNLLZPUHQ-UHFFFAOYSA-N 0.000 description 5
FDWRKMPNEIXNOE-UHFFFAOYSA-N 3-methyl-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=CC=C2NC(C)=NS(=O)(=O)C2=C1 FDWRKMPNEIXNOE-UHFFFAOYSA-N 0.000 description 5
DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 5
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 5
101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 5
241000700159 Rattus Species 0.000 description 5
239000000556 agonist Substances 0.000 description 5
239000012267 brine Substances 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 5
238000001704 evaporation Methods 0.000 description 5
230000008020 evaporation Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000012299 nitrogen atmosphere Substances 0.000 description 5
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 5
230000036515 potency Effects 0.000 description 5
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
239000007921 spray Substances 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
QDRZCTURWDQVCY-UHFFFAOYSA-N 2-amino-5-cyanobenzenesulfonamide Chemical compound NC1=CC=C(C#N)C=C1S(N)(=O)=O QDRZCTURWDQVCY-UHFFFAOYSA-N 0.000 description 4
NJZLACFKUHUTCX-UHFFFAOYSA-N 2-amino-6-methylbenzenesulfonamide Chemical compound CC1=CC=CC(N)=C1S(N)(=O)=O NJZLACFKUHUTCX-UHFFFAOYSA-N 0.000 description 4
FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 4
RGDFUTUYFYKNHL-UHFFFAOYSA-N 3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1S(=O)(=O)C2=CC(S(=O)(=O)N)=CC=C2NC1C1CCCCC1 RGDFUTUYFYKNHL-UHFFFAOYSA-N 0.000 description 4
GVMZEULNBBKLON-UHFFFAOYSA-N 3-cyclohexyl-4-methyl-7-morpholin-4-ylsulfonyl-2,3-dihydro-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2N(C)C(C3CCCCC3)NS(=O)(=O)C2=CC=1S(=O)(=O)N1CCOCC1 GVMZEULNBBKLON-UHFFFAOYSA-N 0.000 description 4
RVSVPOUZDNHJSI-UHFFFAOYSA-N 3-cyclohexyl-n,n-diethyl-5-methyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1S(=O)(=O)C2=CC(S(=O)(=O)N(CC)CC)=CC(C)=C2NC1C1CCCCC1 RVSVPOUZDNHJSI-UHFFFAOYSA-N 0.000 description 4
JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 4
CYWNPYZEJFXETN-UHFFFAOYSA-N 5-chloro-3-cyclohexyl-8-(2-methoxyphenyl)-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound COC1=CC=CC=C1C1=CC=C(Cl)C2=C1S(=O)(=O)NC(C1CCCCC1)=N2 CYWNPYZEJFXETN-UHFFFAOYSA-N 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
239000007995 HEPES buffer Substances 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
230000004913 activation Effects 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
239000000969 carrier Substances 0.000 description 4
210000003618 cortical neuron Anatomy 0.000 description 4
JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
230000004907 flux Effects 0.000 description 4
210000002683 foot Anatomy 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
230000001057 ionotropic effect Effects 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
229910052763 palladium Inorganic materials 0.000 description 4
FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
239000000375 suspending agent Substances 0.000 description 4
239000002562 thickening agent Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 4
SFUIGUOONHIVLG-UHFFFAOYSA-N (2-nitrophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1[N+]([O-])=O SFUIGUOONHIVLG-UHFFFAOYSA-N 0.000 description 3
SYZKMHCUETXUAM-UHFFFAOYSA-N 2,2-dimethyl-n-(4-pyrimidin-2-ylphenyl)propanamide Chemical compound C1=CC(NC(=O)C(C)(C)C)=CC=C1C1=NC=CC=N1 SYZKMHCUETXUAM-UHFFFAOYSA-N 0.000 description 3
GVOYKJPMUUJXBS-UHFFFAOYSA-N 2-(aminomethyl)aniline Chemical compound NCC1=CC=CC=C1N GVOYKJPMUUJXBS-UHFFFAOYSA-N 0.000 description 3
SZWRFMZUFNVSCI-UHFFFAOYSA-N 2-[(2,2,2-trifluoroacetyl)amino]benzamide Chemical compound NC(=O)C1=CC=CC=C1NC(=O)C(F)(F)F SZWRFMZUFNVSCI-UHFFFAOYSA-N 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 3
UOCUSOBVEHOMMB-UHFFFAOYSA-N 2h-1$l^{6},2,3-benzothiadiazine 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)NN=CC2=C1 UOCUSOBVEHOMMB-UHFFFAOYSA-N 0.000 description 3
PZSOUKUHRNHSSO-UHFFFAOYSA-N 3-cyclohexyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-7-amine Chemical compound N1S(=O)(=O)C2=CC(N)=CC=C2N=C1C1CCCCC1 PZSOUKUHRNHSSO-UHFFFAOYSA-N 0.000 description 3
NAYYRCQJMRTILN-UHFFFAOYSA-N 3-cyclohexyl-7-[2-methoxy-4-(trifluoromethyl)phenyl]-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound COC1=CC(C(F)(F)F)=CC=C1C1=CC=C(NC(NS2(=O)=O)C3CCCCC3)C2=C1 NAYYRCQJMRTILN-UHFFFAOYSA-N 0.000 description 3
GAKRBMKZZKBZSD-UHFFFAOYSA-N 3-cyclohexyl-7-nitro-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound N1S(=O)(=O)C2=CC([N+](=O)[O-])=CC=C2NC1C1CCCCC1 GAKRBMKZZKBZSD-UHFFFAOYSA-N 0.000 description 3
BOZSDDFQWJUBNG-UHFFFAOYSA-N 4-aminobenzene-1,3-disulfonamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1S(N)(=O)=O BOZSDDFQWJUBNG-UHFFFAOYSA-N 0.000 description 3
BMILSKQXYNRTKK-UHFFFAOYSA-N 5-acetyl-2-aminobenzenesulfonamide Chemical compound CC(=O)C1=CC=C(N)C(S(N)(=O)=O)=C1 BMILSKQXYNRTKK-UHFFFAOYSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
102000018899 Glutamate Receptors Human genes 0.000 description 3
108010027915 Glutamate Receptors Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000000079 Kainic Acid Receptors Human genes 0.000 description 3
108010069902 Kainic Acid Receptors Proteins 0.000 description 3
238000011785 NMRI mouse Methods 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
DZULQZKFBAHSRX-UHFFFAOYSA-N adamantane-1-carbaldehyde Chemical compound C1C(C2)CC3CC2CC1(C=O)C3 DZULQZKFBAHSRX-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
150000001448 anilines Chemical class 0.000 description 3
ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 3
229960000793 aniracetam Drugs 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
150000001499 aryl bromides Chemical class 0.000 description 3
238000003556 assay Methods 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
239000003086 colorant Substances 0.000 description 3
239000006071 cream Substances 0.000 description 3
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
230000002964 excitative effect Effects 0.000 description 3
125000002541 furyl group Chemical group 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
210000004295 hippocampal neuron Anatomy 0.000 description 3
125000002883 imidazolyl group Chemical group 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 3
230000027928 long-term synaptic potentiation Effects 0.000 description 3
239000007937 lozenge Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
KJMIEMXCSZWVPP-UHFFFAOYSA-N n-(3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazin-7-yl)methanesulfonamide Chemical compound N1S(=O)(=O)C2=CC(NS(=O)(=O)C)=CC=C2NC1C1CCCCC1 KJMIEMXCSZWVPP-UHFFFAOYSA-N 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 3
239000006215 rectal suppository Substances 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
229960000581 salicylamide Drugs 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
125000001544 thienyl group Chemical group 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
UMOPBIVXPOETPG-UHFFFAOYSA-N (2-acetamidophenyl)boronic acid Chemical compound CC(=O)NC1=CC=CC=C1B(O)O UMOPBIVXPOETPG-UHFFFAOYSA-N 0.000 description 2
DIRRKLFMHQUJCM-UHFFFAOYSA-N (2-aminophenyl)boronic acid Chemical compound NC1=CC=CC=C1B(O)O DIRRKLFMHQUJCM-UHFFFAOYSA-N 0.000 description 2
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
WSPLSEINYOFEAL-UHFFFAOYSA-N (5-chloro-3-cyclohexyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-8-yl)boronic acid Chemical compound N1S(=O)(=O)C=2C(B(O)O)=CC=C(Cl)C=2N=C1C1CCCCC1 WSPLSEINYOFEAL-UHFFFAOYSA-N 0.000 description 2
RTNBYRCCHKLPFQ-UHFFFAOYSA-N 1-(3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazin-7-yl)ethanone Chemical compound N1S(=O)(=O)C2=CC(C(=O)C)=CC=C2NC1C1CCCCC1 RTNBYRCCHKLPFQ-UHFFFAOYSA-N 0.000 description 2
CFIPQRIPCRRISV-UHFFFAOYSA-N 1-methoxy-4-(trifluoromethyl)benzene Chemical compound COC1=CC=C(C(F)(F)F)C=C1 CFIPQRIPCRRISV-UHFFFAOYSA-N 0.000 description 2
MWIYRLXMLHRLDT-UHFFFAOYSA-N 1-methylsulfonylpiperazin-4-ium;chloride Chemical compound Cl.CS(=O)(=O)N1CCNCC1 MWIYRLXMLHRLDT-UHFFFAOYSA-N 0.000 description 2
IAWXTSMHXFRLQR-UHFFFAOYSA-N 2,3-bis($l^{1}-oxidanyl)-7-nitroquinoxaline-6-carbonitrile Chemical compound O=C1C(=O)N=C2C=C(C#N)C([N+](=O)[O-])=CC2=N1 IAWXTSMHXFRLQR-UHFFFAOYSA-N 0.000 description 2
CZZZABOKJQXEBO-UHFFFAOYSA-N 2,4-dimethylaniline Chemical compound CC1=CC=C(N)C(C)=C1 CZZZABOKJQXEBO-UHFFFAOYSA-N 0.000 description 2
NAIJZCXBMHHHDM-UHFFFAOYSA-N 2-(aminomethyl)-4,6-dibromoaniline Chemical compound NCC1=CC(Br)=CC(Br)=C1N NAIJZCXBMHHHDM-UHFFFAOYSA-N 0.000 description 2
HJIYHFTUASVPDO-UHFFFAOYSA-N 2-amino-4-bromo-5-methylbenzenesulfonamide Chemical compound CC1=CC(S(N)(=O)=O)=C(N)C=C1Br HJIYHFTUASVPDO-UHFFFAOYSA-N 0.000 description 2
KQDZEDHMFMVZRU-UHFFFAOYSA-N 2-amino-4-methoxybenzenesulfonamide Chemical compound COC1=CC=C(S(N)(=O)=O)C(N)=C1 KQDZEDHMFMVZRU-UHFFFAOYSA-N 0.000 description 2
ORSPUWDSVNUZGD-UHFFFAOYSA-N 2-amino-5-(1-hydroxyethyl)benzenesulfonamide Chemical compound CC(O)C1=CC=C(N)C(S(N)(=O)=O)=C1 ORSPUWDSVNUZGD-UHFFFAOYSA-N 0.000 description 2
BGILQOXCWMHWOM-UHFFFAOYSA-N 2-amino-5-bromobenzenesulfonamide Chemical compound NC1=CC=C(Br)C=C1S(N)(=O)=O BGILQOXCWMHWOM-UHFFFAOYSA-N 0.000 description 2
AMZRLVJMBHMIPA-UHFFFAOYSA-N 2-phenyl-2,3-dihydro-1,3-benzoxazin-4-one Chemical compound O1C2=CC=CC=C2C(=O)NC1C1=CC=CC=C1 AMZRLVJMBHMIPA-UHFFFAOYSA-N 0.000 description 2
VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 2
PPQBNARNKKDRMX-UHFFFAOYSA-N 3-(2-methylpropyl)-1,1-dioxo-3,5-dihydro-2h-1$l^{6},2,5-benzothiadiazepin-4-one Chemical compound N1C(=O)C(CC(C)C)NS(=O)(=O)C2=CC=CC=C21 PPQBNARNKKDRMX-UHFFFAOYSA-N 0.000 description 2
UYRZSQPPZIJHEH-UHFFFAOYSA-N 3-(3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazin-7-yl)phenol Chemical compound OC1=CC=CC(C=2C=C3S(=O)(=O)NC(NC3=CC=2)C2CCCCC2)=C1 UYRZSQPPZIJHEH-UHFFFAOYSA-N 0.000 description 2
MAWXPZVCLQIKFJ-UHFFFAOYSA-N 3-(trifluoromethyl)-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)NC(C(F)(F)F)=NC2=C1 MAWXPZVCLQIKFJ-UHFFFAOYSA-N 0.000 description 2
WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 2
DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 2
IWCUSNNKTQYZRR-UHFFFAOYSA-N 3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-carboxamide Chemical compound N1S(=O)(=O)C2=CC(C(=O)N)=CC=C2NC1C1CCCCC1 IWCUSNNKTQYZRR-UHFFFAOYSA-N 0.000 description 2
YRIQILHDDTZHQG-UHFFFAOYSA-N 3-cyclohexyl-2-methyl-7-morpholin-4-ylsulfonyl-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=C2S(=O)(=O)N(C)C(C3CCCCC3)=NC2=CC=C1S(=O)(=O)N1CCOCC1 YRIQILHDDTZHQG-UHFFFAOYSA-N 0.000 description 2
YHCXRGBPUHDXAT-UHFFFAOYSA-N 3-cyclohexyl-6-methyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1S(=O)(=O)C=2C=C(S(N)(=O)=O)C(C)=CC=2NC1C1CCCCC1 YHCXRGBPUHDXAT-UHFFFAOYSA-N 0.000 description 2
HSZBKGKHBRMYTR-UHFFFAOYSA-N 3-cyclohexyl-7-(2-fluorophenyl)-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound FC1=CC=CC=C1C1=CC=C(NC(NS2(=O)=O)C3CCCCC3)C2=C1 HSZBKGKHBRMYTR-UHFFFAOYSA-N 0.000 description 2
IPUSXJYULKXAIU-UHFFFAOYSA-N 3-cyclohexyl-7-cyclopentylsulfinyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2NC(C3CCCCC3)NS(=O)(=O)C2=CC=1S(=O)C1CCCC1 IPUSXJYULKXAIU-UHFFFAOYSA-N 0.000 description 2
MVTZQPQXMILNFA-UHFFFAOYSA-N 3-cyclohexyl-7-morpholin-4-ylsulfonyl-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2N=C(C3CCCCC3)NS(=O)(=O)C2=CC=1S(=O)(=O)N1CCOCC1 MVTZQPQXMILNFA-UHFFFAOYSA-N 0.000 description 2
MIMZXASTBXVWAV-UHFFFAOYSA-N 3-cyclohexyl-7-nitro-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound N1S(=O)(=O)C2=CC([N+](=O)[O-])=CC=C2N=C1C1CCCCC1 MIMZXASTBXVWAV-UHFFFAOYSA-N 0.000 description 2
IQFNPEAFZJFJFO-UHFFFAOYSA-N 3-cyclohexyl-8-methoxy-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound N1S(=O)(=O)C=2C(OC)=CC=CC=2NC1C1CCCCC1 IQFNPEAFZJFJFO-UHFFFAOYSA-N 0.000 description 2
NFNLNGKUBOUUEO-UHFFFAOYSA-N 3-ethyl-6-methoxy-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound COC1=CC=C2S(=O)(=O)NC(CC)=NC2=C1 NFNLNGKUBOUUEO-UHFFFAOYSA-N 0.000 description 2
OBZUMOZIMMQMPW-UHFFFAOYSA-N 3-methyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(C)=NC2=C1 OBZUMOZIMMQMPW-UHFFFAOYSA-N 0.000 description 2
XFAUQNOCFCXERV-UHFFFAOYSA-N 3-methyl-7-piperidin-1-ylsulfonyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=C2S(=O)(=O)NC(C)NC2=CC=C1S(=O)(=O)N1CCCCC1 XFAUQNOCFCXERV-UHFFFAOYSA-N 0.000 description 2
PMMNAVXGIVYGHU-UHFFFAOYSA-N 3-phenyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound N1C2=CC=CC=C2S(=O)(=O)NC1C1=CC=CC=C1 PMMNAVXGIVYGHU-UHFFFAOYSA-N 0.000 description 2
YLNMGMIEOWFPRX-UHFFFAOYSA-N 3-pyridin-2-ylaniline Chemical compound NC1=CC=CC(C=2N=CC=CC=2)=C1 YLNMGMIEOWFPRX-UHFFFAOYSA-N 0.000 description 2
OPKQRYBDJWZCFW-UHFFFAOYSA-N 4-amino-5-bromobenzene-1,3-disulfonamide Chemical compound NC1=C(Br)C=C(S(N)(=O)=O)C=C1S(N)(=O)=O OPKQRYBDJWZCFW-UHFFFAOYSA-N 0.000 description 2
VXDRFVIORCJOLM-UHFFFAOYSA-N 4-amino-n'-hydroxy-3-sulfamoylbenzenecarboximidamide Chemical compound NC1=CC=C(C(=N)NO)C=C1S(N)(=O)=O VXDRFVIORCJOLM-UHFFFAOYSA-N 0.000 description 2
RUVNVJCKWOOLOH-UHFFFAOYSA-N 4-pyrimidin-2-ylaniline Chemical compound C1=CC(N)=CC=C1C1=NC=CC=N1 RUVNVJCKWOOLOH-UHFFFAOYSA-N 0.000 description 2
BBNGVMNBBLPZIR-UHFFFAOYSA-N 4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)N=CNC2=C1 BBNGVMNBBLPZIR-UHFFFAOYSA-N 0.000 description 2
MUAILCDCWHRBKJ-UHFFFAOYSA-N 5-chloro-3-cyclohexyl-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound ClC1=CC=CC(S(N2)(=O)=O)=C1N=C2C1CCCCC1 MUAILCDCWHRBKJ-UHFFFAOYSA-N 0.000 description 2
MNKFCGJSEZARPQ-UHFFFAOYSA-N 5-chloro-3-cyclohexyl-8-iodo-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound ClC1=CC=C(I)C(S(N2)(=O)=O)=C1N=C2C1CCCCC1 MNKFCGJSEZARPQ-UHFFFAOYSA-N 0.000 description 2
VTZHJBKTNYFWBP-UHFFFAOYSA-N 5-chloro-3-cyclohexyl-8-pyridin-2-yl-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound N1=C(C2CCCCC2)NS(=O)(=O)C2=C1C(Cl)=CC=C2C1=CC=CC=N1 VTZHJBKTNYFWBP-UHFFFAOYSA-N 0.000 description 2
YPDKVAXWZXEANV-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3-phenyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1=CC=CC=C1 YPDKVAXWZXEANV-UHFFFAOYSA-N 0.000 description 2
IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 2
229910018072 Al 2 O 3 Inorganic materials 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
XFFAPLAFBRHYDV-UHFFFAOYSA-N C1CCC(CC1)C2NC3=CCC(C=C3S(=O)(=O)N2)S(=O)(=O)N Chemical compound C1CCC(CC1)C2NC3=CCC(C=C3S(=O)(=O)N2)S(=O)(=O)N XFFAPLAFBRHYDV-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 2
AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
229910010082 LiAlH Inorganic materials 0.000 description 2
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
244000299461 Theobroma cacao Species 0.000 description 2
235000009470 Theobroma cacao Nutrition 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
GCHDOHKUPJUTCB-UHFFFAOYSA-N [2-(dimethylsulfamoyl)phenyl]boronic acid Chemical compound CN(C)S(=O)(=O)C1=CC=CC=C1B(O)O GCHDOHKUPJUTCB-UHFFFAOYSA-N 0.000 description 2
PXDQUMRSSQYJSX-UHFFFAOYSA-N [2-methoxy-5-(trifluoromethyl)phenyl]boronic acid Chemical compound COC1=CC=C(C(F)(F)F)C=C1B(O)O PXDQUMRSSQYJSX-UHFFFAOYSA-N 0.000 description 2
ORNCMGDXLWQRHH-UHFFFAOYSA-N [4-(2,2-dimethylpropanoylamino)phenyl]boronic acid Chemical compound CC(C)(C)C(=O)NC1=CC=C(B(O)O)C=C1 ORNCMGDXLWQRHH-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000012346 acetyl chloride Substances 0.000 description 2
GTZCVFVGUGFEME-UHFFFAOYSA-N aconitic acid Chemical compound OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 2
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
230000003276 anti-hypertensive effect Effects 0.000 description 2
150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
150000001503 aryl iodides Chemical class 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
150000003857 carboxamides Chemical class 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
210000003710 cerebral cortex Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
IHJCXVZDYSXXFT-UHFFFAOYSA-N chloraminophenamide Chemical compound NC1=CC(Cl)=C(S(N)(=O)=O)C=C1S(N)(=O)=O IHJCXVZDYSXXFT-UHFFFAOYSA-N 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
238000006880 cross-coupling reaction Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 description 2
229960003176 cyclothiazide Drugs 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
238000000586 desensitisation Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
OJKBCQOJVMAHDX-UHFFFAOYSA-N diethyl(pyridin-3-yl)borane Chemical compound CCB(CC)C1=CC=CN=C1 OJKBCQOJVMAHDX-UHFFFAOYSA-N 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
208000037765 diseases and disorders Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
230000005284 excitation Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
238000001640 fractional crystallisation Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
125000001072 heteroaryl group Chemical group 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
239000011630 iodine Substances 0.000 description 2
KPJPHPFMCOKUMW-UHFFFAOYSA-N iodomethane Chemical compound I[CH2] KPJPHPFMCOKUMW-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
239000006210 lotion Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000028161 membrane depolarization Effects 0.000 description 2
102000006239 metabotropic receptors Human genes 0.000 description 2
108020004083 metabotropic receptors Proteins 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
ALMHSXDYCFOZQD-UHFFFAOYSA-N n-(3-methylphenyl)acetamide Chemical compound CC(=O)NC1=CC=CC(C)=C1 ALMHSXDYCFOZQD-UHFFFAOYSA-N 0.000 description 2
HNBBRWKIAGAVKP-UHFFFAOYSA-N n-(5,5-dioxo-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazin-7-yl)methanesulfonamide Chemical compound N1S(=O)(=O)C2=CC(NS(=O)(=O)C)=CC=C2N2CCCC21 HNBBRWKIAGAVKP-UHFFFAOYSA-N 0.000 description 2
WPIVFLLXECMSME-UHFFFAOYSA-N n-[2-(3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazin-7-yl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=CC=C(NC(NS2(=O)=O)C3CCCCC3)C2=C1 WPIVFLLXECMSME-UHFFFAOYSA-N 0.000 description 2
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 2
210000003928 nasal cavity Anatomy 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 2
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
239000002674 ointment Substances 0.000 description 2
125000001715 oxadiazolyl group Chemical group 0.000 description 2
SQYNKIJPMDEDEG-UHFFFAOYSA-N paraldehyde Chemical compound CC1OC(C)OC(C)O1 SQYNKIJPMDEDEG-UHFFFAOYSA-N 0.000 description 2
229960003868 paraldehyde Drugs 0.000 description 2
239000002245 particle Substances 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
235000010333 potassium nitrate Nutrition 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
125000004076 pyridyl group Chemical group 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000012258 stirred mixture Substances 0.000 description 2
238000005849 sulfamoylation reaction Methods 0.000 description 2
230000000946 synaptic effect Effects 0.000 description 2
CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 2
229950010357 tetrodotoxin Drugs 0.000 description 2
CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
150000003852 triazoles Chemical class 0.000 description 2
125000001425 triazolyl group Chemical group 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
238000001665 trituration Methods 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
239000001993 wax Substances 0.000 description 2
238000005303 weighing Methods 0.000 description 2
DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
YFYNOWXBIBKGHB-MHTLYPKNSA-N (1r,3s)-1-aminocyclopentane-1,3-dicarboxylic acid Chemical compound OC(=O)[C@@]1(N)CC[C@H](C(O)=O)C1 YFYNOWXBIBKGHB-MHTLYPKNSA-N 0.000 description 1
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
SQTUYFKNCCBFRR-UHFFFAOYSA-N (2,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(OC)=C1 SQTUYFKNCCBFRR-UHFFFAOYSA-N 0.000 description 1
RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 1
QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
FHGGSFLCDUKYQL-UHFFFAOYSA-N (3-aminophenyl)boronic acid;3-cyclohexyl-6-pyridin-2-yl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound NC1=CC=CC(B(O)O)=C1.C=1C=C2S(=O)(=O)NC(C3CCCCC3)NC2=CC=1C1=CC=CC=N1 FHGGSFLCDUKYQL-UHFFFAOYSA-N 0.000 description 1
DELZLWFWIQHBII-UHFFFAOYSA-N (3-cyclohexyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-8-yl)methanol Chemical compound N1S(=O)(=O)C=2C(CO)=CC=CC=2N=C1C1CCCCC1 DELZLWFWIQHBII-UHFFFAOYSA-N 0.000 description 1
WFWQWTPAPNEOFE-UHFFFAOYSA-N (3-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(O)=C1 WFWQWTPAPNEOFE-UHFFFAOYSA-N 0.000 description 1
NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 1
FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
LCDBKCCPUXCASM-UHFFFAOYSA-N 1,1-dioxo-3-phenyl-4h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1S(=O)(=O)C2=CC(S(=O)(=O)N)=CC=C2N=C1C1=CC=CC=C1 LCDBKCCPUXCASM-UHFFFAOYSA-N 0.000 description 1
125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 1
125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 description 1
125000004507 1,2,5-oxadiazol-3-yl group Chemical group O1N=C(C=N1)* 0.000 description 1
125000004508 1,2,5-oxadiazol-4-yl group Chemical group O1N=CC(=N1)* 0.000 description 1
125000004518 1,2,5-thiadiazol-3-yl group Chemical group S1N=C(C=N1)* 0.000 description 1
125000004519 1,2,5-thiadiazol-4-yl group Chemical group S1N=CC(=N1)* 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
NJOKEXZCVFGHAC-UHFFFAOYSA-N 1,3-benzodioxol-5-yl(3,6-dihydro-2h-pyridin-1-yl)methanone Chemical compound C=1C=C2OCOC2=CC=1C(=O)N1CCC=CC1 NJOKEXZCVFGHAC-UHFFFAOYSA-N 0.000 description 1
VPPMWVKTJWIMOY-UHFFFAOYSA-N 1,3-diazocane Chemical compound C1CCNCNCC1 VPPMWVKTJWIMOY-UHFFFAOYSA-N 0.000 description 1
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
CXPUAWQOXQINEX-UHFFFAOYSA-N 1,4-diazocane Chemical compound C1CCNCCNC1 CXPUAWQOXQINEX-UHFFFAOYSA-N 0.000 description 1
GOFIUEUUROFVMA-UHFFFAOYSA-N 1-(1h-indol-5-yl)ethanone Chemical compound CC(=O)C1=CC=C2NC=CC2=C1 GOFIUEUUROFVMA-UHFFFAOYSA-N 0.000 description 1
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
XLQSXGGDTHANLN-UHFFFAOYSA-N 1-bromo-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(Br)C=C1 XLQSXGGDTHANLN-UHFFFAOYSA-N 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
125000006017 1-propenyl group Chemical group 0.000 description 1
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 1
UQNAFPHGVPVTAL-UHFFFAOYSA-N 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+]([O-])=O)C1=C2C=CC=C1S(=O)(=O)N UQNAFPHGVPVTAL-UHFFFAOYSA-N 0.000 description 1
BZKOZYWGZKRTIB-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-6-amine Chemical compound O1CCOC2=CC(N)=CC=C21 BZKOZYWGZKRTIB-UHFFFAOYSA-N 0.000 description 1
QUJSOIUCVUAWFG-UHFFFAOYSA-N 2,3-dihydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide N-(5,5-dioxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazin-7-yl)methanesulfonamide Chemical compound C1CCC2=NS(C3=C(N21)C=CC=C3)(=O)=O.CS(=O)(=O)NC3=CC2=C(N1C(NS2(=O)=O)CCC1)C=C3 QUJSOIUCVUAWFG-UHFFFAOYSA-N 0.000 description 1
HWOJZNGWXRYGBY-UHFFFAOYSA-N 2,3-dihydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound C12=CC=CC=C2S(=O)(=O)N=C2N1CCC2 HWOJZNGWXRYGBY-UHFFFAOYSA-N 0.000 description 1
KQCMTOWTPBNWDB-UHFFFAOYSA-N 2,4-dichloroaniline Chemical compound NC1=CC=C(Cl)C=C1Cl KQCMTOWTPBNWDB-UHFFFAOYSA-N 0.000 description 1
WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
BQFHXNJPWFQYES-UHFFFAOYSA-N 2-(3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazin-7-yl)-n,n-dimethylbenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(NS2(=O)=O)C3CCCCC3)C2=C1 BQFHXNJPWFQYES-UHFFFAOYSA-N 0.000 description 1
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
BVUHMJUCTZMRIC-UHFFFAOYSA-N 2-amino-3-bromobenzenesulfonamide Chemical compound NC1=C(Br)C=CC=C1S(N)(=O)=O BVUHMJUCTZMRIC-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
DJRSQBMMKFMDSM-UHFFFAOYSA-N 2-amino-4-(2-methoxyphenyl)-5-methylbenzenesulfonamide Chemical compound COC1=CC=CC=C1C1=CC(N)=C(S(N)(=O)=O)C=C1C DJRSQBMMKFMDSM-UHFFFAOYSA-N 0.000 description 1
NIOMGLAJJGMNEO-UHFFFAOYSA-N 2-amino-4-(2-methoxyphenyl)benzenesulfonamide Chemical compound COC1=CC=CC=C1C1=CC=C(S(N)(=O)=O)C(N)=C1 NIOMGLAJJGMNEO-UHFFFAOYSA-N 0.000 description 1
STNUHHSMYIGELS-UHFFFAOYSA-N 2-amino-4-methyl-5-pyridin-2-ylbenzenesulfonamide Chemical compound CC1=CC(N)=C(S(N)(=O)=O)C=C1C1=CC=CC=N1 STNUHHSMYIGELS-UHFFFAOYSA-N 0.000 description 1
ZIHFDPNPDKLITA-UHFFFAOYSA-N 2-amino-4-pyridin-3-ylbenzenesulfonamide Chemical compound C1=C(S(N)(=O)=O)C(N)=CC(C=2C=NC=CC=2)=C1 ZIHFDPNPDKLITA-UHFFFAOYSA-N 0.000 description 1
JIPMAGKDUDKWJT-UHFFFAOYSA-N 2-amino-5-(1-methylimidazol-2-yl)benzenesulfonamide Chemical compound CN1C=CN=C1C1=CC=C(N)C(S(N)(=O)=O)=C1 JIPMAGKDUDKWJT-UHFFFAOYSA-N 0.000 description 1
QPEGWPQPDSUWLG-UHFFFAOYSA-N 2-amino-5-(N-hydroxy-C-methylcarbonimidoyl)benzenesulfonamide Chemical compound ON=C(C)C1=CC=C(N)C(S(N)(=O)=O)=C1 QPEGWPQPDSUWLG-UHFFFAOYSA-N 0.000 description 1
LJOYWSGHBXEHOH-UHFFFAOYSA-N 2-amino-5-cyanobenzenesulfonamide 3-cyclohexyl-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-carbonitrile Chemical compound Nc1ccc(cc1S(N)(=O)=O)C#N.O=S1(=O)NC(Nc2ccc(cc12)C#N)C1CCCCC1 LJOYWSGHBXEHOH-UHFFFAOYSA-N 0.000 description 1
DEPALZAXAXCTLH-UHFFFAOYSA-N 2-amino-6-bromobenzenesulfonamide Chemical compound NC1=CC=CC(Br)=C1S(N)(=O)=O DEPALZAXAXCTLH-UHFFFAOYSA-N 0.000 description 1
YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
KPYGGUJZBSKSPQ-UHFFFAOYSA-N 2-aminobenzenesulfonamide;5,5-dioxo-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine-7-sulfonamide Chemical compound NC1=CC=CC=C1S(N)(=O)=O.N1S(=O)(=O)C2=CC(S(=O)(=O)N)=CC=C2N2CCCC21 KPYGGUJZBSKSPQ-UHFFFAOYSA-N 0.000 description 1
VLGATQIVLCMXCP-UHFFFAOYSA-N 2-aminobenzenesulfonamide;n-cyclohexyl-5,5-dioxo-2,3-dihydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine-7-sulfonamide Chemical compound NC1=CC=CC=C1S(N)(=O)=O.C=1C=C2N3CCCC3=NS(=O)(=O)C2=CC=1S(=O)(=O)NC1CCCCC1 VLGATQIVLCMXCP-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
MKQNYQGIPARLKO-UHFFFAOYSA-N 2-methoxybenzenesulfonamide Chemical compound COC1=CC=CC=C1S(N)(=O)=O MKQNYQGIPARLKO-UHFFFAOYSA-N 0.000 description 1
DHEKCFIOOSCJRW-UHFFFAOYSA-N 2-methylheptanal Chemical compound CCCCCC(C)C=O DHEKCFIOOSCJRW-UHFFFAOYSA-N 0.000 description 1
WPHUUIODWRNJLO-UHFFFAOYSA-N 2-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1S(Cl)(=O)=O WPHUUIODWRNJLO-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
QHDSJIAGHURUSW-UHFFFAOYSA-N 3,5-dibromobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC(Br)=CC(Br)=C1 QHDSJIAGHURUSW-UHFFFAOYSA-N 0.000 description 1
DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
QQCHBWKNLRGAJA-UHFFFAOYSA-N 3-(trifluoromethyl)-2H-1,2,4-benzothiadiazine Chemical class FC(C=1NSC2=C(N1)C=CC=C2)(F)F QQCHBWKNLRGAJA-UHFFFAOYSA-N 0.000 description 1
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
TWKHKGLZYOYXFQ-UHFFFAOYSA-N 3-benzyl-7-piperidin-1-ylsulfonyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2NC(CC=3C=CC=CC=3)NS(=O)(=O)C2=CC=1S(=O)(=O)N1CCCCC1 TWKHKGLZYOYXFQ-UHFFFAOYSA-N 0.000 description 1
LWHKUVOYICRGGR-UHFFFAOYSA-N 3-bicyclo[2.2.1]heptanylmethanol Chemical compound C1CC2C(CO)CC1C2 LWHKUVOYICRGGR-UHFFFAOYSA-N 0.000 description 1
GRXMMIBZRMKADT-UHFFFAOYSA-N 3-bromo-4-methylaniline Chemical compound CC1=CC=C(N)C=C1Br GRXMMIBZRMKADT-UHFFFAOYSA-N 0.000 description 1
XGTSDUSKGROCGF-UHFFFAOYSA-N 3-bromoaniline;3-cyclohexyl-6-(2-methoxyphenyl)-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound NC1=CC=CC(Br)=C1.COC1=CC=CC=C1C1=CC=C2S(=O)(=O)NC(C3CCCCC3)NC2=C1 XGTSDUSKGROCGF-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
IXKMHMLMLKFTME-UHFFFAOYSA-N 3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazin-7-amine Chemical compound N1S(=O)(=O)C2=CC(N)=CC=C2NC1C1CCCCC1 IXKMHMLMLKFTME-UHFFFAOYSA-N 0.000 description 1
CBOJNEUNMKHDOA-UHFFFAOYSA-N 3-cyclohexyl-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound N=1C2=CC=CC=C2S(=O)(=O)NC=1C1CCCCC1 CBOJNEUNMKHDOA-UHFFFAOYSA-N 0.000 description 1
RKQNBZGBUDFCGQ-UHFFFAOYSA-N 3-cyclohexyl-6-(2-methoxyphenyl)-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound COC1=CC=CC=C1C1=CC=C2S(=O)(=O)NC(C3CCCCC3)NC2=C1 RKQNBZGBUDFCGQ-UHFFFAOYSA-N 0.000 description 1
LRCGUNBQJCEZLA-UHFFFAOYSA-N 3-cyclohexyl-6-pyridin-2-yl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2S(=O)(=O)NC(C3CCCCC3)NC2=CC=1C1=CC=CC=N1 LRCGUNBQJCEZLA-UHFFFAOYSA-N 0.000 description 1
XQGOTBKWRIITFK-UHFFFAOYSA-N 3-cyclohexyl-7-piperidin-1-ylsulfonyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2NC(C3CCCCC3)NS(=O)(=O)C2=CC=1S(=O)(=O)N1CCCCC1 XQGOTBKWRIITFK-UHFFFAOYSA-N 0.000 description 1
BVIBNZOODYXJEB-UHFFFAOYSA-N 3-cyclohexyl-n,n-diethyl-5-formyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1S(=O)(=O)C2=CC(S(=O)(=O)N(CC)CC)=CC(C=O)=C2N=C1C1CCCCC1 BVIBNZOODYXJEB-UHFFFAOYSA-N 0.000 description 1
PBGGAGHGTCRBPV-UHFFFAOYSA-N 3-cyclohexyl-n,n-dimethyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1S(=O)(=O)C2=CC(S(=O)(=O)N(C)C)=CC=C2NC1C1CCCCC1 PBGGAGHGTCRBPV-UHFFFAOYSA-N 0.000 description 1
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
GDYFDXDATVPPDR-UHFFFAOYSA-N 4-(benzenesulfonyl)aniline Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=CC=C1 GDYFDXDATVPPDR-UHFFFAOYSA-N 0.000 description 1
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
HRHSLXPVOCYOSZ-UHFFFAOYSA-N 4-amino-6-chlorobenzene-1,3-disulfonamide 6-chloro-3-cyclohexyl-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide Chemical compound Nc1cc(Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O.NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C2CCCCC2)cc1Cl HRHSLXPVOCYOSZ-UHFFFAOYSA-N 0.000 description 1
ALYNCZNDIQEVRV-UHFFFAOYSA-M 4-aminobenzoate Chemical compound NC1=CC=C(C([O-])=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-M 0.000 description 1
VRHVHBIUCNRUOK-UHFFFAOYSA-N 4-methyl-2-[(2-nitrophenyl)sulfonylamino]pentanoic acid Chemical compound CC(C)CC(C(O)=O)NS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O VRHVHBIUCNRUOK-UHFFFAOYSA-N 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
FMYSLCGTEWACRG-UHFFFAOYSA-N 5,5-dioxo-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazin-7-amine Chemical compound N1S(=O)(=O)C2=CC(N)=CC=C2N2CCCC21 FMYSLCGTEWACRG-UHFFFAOYSA-N 0.000 description 1
FVJVJVDGBZSWPL-UHFFFAOYSA-N 5,7-dibromo-3-ethoxy-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=C(Br)C=C2S(=O)(=O)NC(OCC)NC2=C1Br FVJVJVDGBZSWPL-UHFFFAOYSA-N 0.000 description 1
XGOZNHPMPZJDPE-UHFFFAOYSA-N 5,7-dibromo-3-phenyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound N1S(=O)(=O)C2=CC(Br)=CC(Br)=C2NC1C1=CC=CC=C1 XGOZNHPMPZJDPE-UHFFFAOYSA-N 0.000 description 1
VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
CCFPXKOJJHQTRQ-UHFFFAOYSA-N 5-amino-2,3-dihydro-1,4-benzodioxine-6-sulfonamide Chemical class O1CCOC2=CC=C(S(N)(=O)=O)C(N)=C21 CCFPXKOJJHQTRQ-UHFFFAOYSA-N 0.000 description 1
QBZRNQFZUSEDJN-UHFFFAOYSA-N 5-bromo-3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1S(=O)(=O)C2=CC(S(=O)(=O)N)=CC(Br)=C2NC1C1CCCCC1 QBZRNQFZUSEDJN-UHFFFAOYSA-N 0.000 description 1
JLXQXNSDRYTTTC-UHFFFAOYSA-N 5-bromo-7-chloro-3-methyl-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=C(Cl)C=C2S(=O)(=O)NC(C)=NC2=C1Br JLXQXNSDRYTTTC-UHFFFAOYSA-N 0.000 description 1
XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
GSANLKDDFJGLCF-UHFFFAOYSA-N 6-amino-2,3-dihydro-1,4-benzodioxine-5-sulfonamide Chemical compound O1CCOC2=C(S(N)(=O)=O)C(N)=CC=C21 GSANLKDDFJGLCF-UHFFFAOYSA-N 0.000 description 1
GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
HNDPIJYXKATYAZ-UHFFFAOYSA-N 6-chloro-3-cyclohexyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1CCCCC1 HNDPIJYXKATYAZ-UHFFFAOYSA-N 0.000 description 1
FFBZLFOCHFXVJJ-UHFFFAOYSA-N 6-methyl-3-propyl-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound CC1=CC=C2S(=O)(=O)NC(CCC)=NC2=C1 FFBZLFOCHFXVJJ-UHFFFAOYSA-N 0.000 description 1
GGMLWMOUORXJLT-UHFFFAOYSA-N 7-(2-chlorophenyl)-3-cyclohexyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound ClC1=CC=CC=C1C1=CC=C(NC(NS2(=O)=O)C3CCCCC3)C2=C1 GGMLWMOUORXJLT-UHFFFAOYSA-N 0.000 description 1
ZTLWQOQSQNVVLF-UHFFFAOYSA-N 7-bromo-3-phenyl-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound N1S(=O)(=O)C2=CC(Br)=CC=C2N=C1C1=CC=CC=C1 ZTLWQOQSQNVVLF-UHFFFAOYSA-N 0.000 description 1
MOBADZYJHCGSGN-UHFFFAOYSA-N 7-chloro-3-methyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-6-amine Chemical compound NC1=C(Cl)C=C2S(=O)(=O)NC(C)=NC2=C1 MOBADZYJHCGSGN-UHFFFAOYSA-N 0.000 description 1
OUFYLNHETUWRAW-UHFFFAOYSA-N 7-chloro-3-methyl-5-nitro-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=C(Cl)C=C2S(=O)(=O)NC(C)=NC2=C1[N+]([O-])=O OUFYLNHETUWRAW-UHFFFAOYSA-N 0.000 description 1
XBDZXOXYXJPTPN-UHFFFAOYSA-N 7-chloro-3-methyl-6-nitro-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound [O-][N+](=O)C1=C(Cl)C=C2S(=O)(=O)NC(C)=NC2=C1 XBDZXOXYXJPTPN-UHFFFAOYSA-N 0.000 description 1
HZCIDQXNASUMLV-UHFFFAOYSA-N 7-chloro-5-iodo-3-methyl-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=C(Cl)C=C2S(=O)(=O)NC(C)=NC2=C1I HZCIDQXNASUMLV-UHFFFAOYSA-N 0.000 description 1
ZNKXVEDZZBSSRD-UHFFFAOYSA-N 7-nitro-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound N1S(=O)(=O)C2=CC([N+](=O)[O-])=CC=C2N2CCCC21 ZNKXVEDZZBSSRD-UHFFFAOYSA-N 0.000 description 1
NKNLFXIZWFYFSF-UHFFFAOYSA-N 7-nitro-2,3-dihydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound O=S1(=O)C2=CC([N+](=O)[O-])=CC=C2N2CCCC2=N1 NKNLFXIZWFYFSF-UHFFFAOYSA-N 0.000 description 1
SEANJJJOFFKBQQ-UHFFFAOYSA-N 7-piperidin-1-ylsulfonyl-3-propyl-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=C2S(=O)(=O)NC(CCC)NC2=CC=C1S(=O)(=O)N1CCCCC1 SEANJJJOFFKBQQ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
239000000774 AMPA receptor agonist Substances 0.000 description 1
229940098747 AMPA receptor antagonist Drugs 0.000 description 1
239000000775 AMPA receptor antagonist Substances 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
RJRUVAGMQXLLPK-UHFFFAOYSA-N BrC1=CC=2NC(C3CCCCC3)NS(=O)(=O)C=2C=C1S(=O)(=O)N1CCCCC1 Chemical compound BrC1=CC=2NC(C3CCCCC3)NS(=O)(=O)C=2C=C1S(=O)(=O)N1CCCCC1 RJRUVAGMQXLLPK-UHFFFAOYSA-N 0.000 description 1
238000006418 Brown reaction Methods 0.000 description 1
241000208199 Buxus sempervirens Species 0.000 description 1
JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
HNNWOOHIAJJLSY-UHFFFAOYSA-N CC(CC(C(=O)O)NS(=O)(=O)C1=C(C=CC=C1)[N+](=O)[O-])C.C(C(C)C)C1NS(C2=C(NC1)C=CC(=C2)S(=O)(=O)N2CCCCC2)(=O)=O Chemical compound CC(CC(C(=O)O)NS(=O)(=O)C1=C(C=CC=C1)[N+](=O)[O-])C.C(C(C)C)C1NS(C2=C(NC1)C=CC(=C2)S(=O)(=O)N2CCCCC2)(=O)=O HNNWOOHIAJJLSY-UHFFFAOYSA-N 0.000 description 1
KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
LVRCEUVOXCJYSV-UHFFFAOYSA-N CN(C)S(=O)=O Chemical compound CN(C)S(=O)=O LVRCEUVOXCJYSV-UHFFFAOYSA-N 0.000 description 1
YYTHOTQYXLODRO-UHFFFAOYSA-N COC1=CC=2NC(C3CCCCC3)NS(=O)(=O)C=2C=C1S(=O)(=O)N1CCCCC1 Chemical compound COC1=CC=2NC(C3CCCCC3)NS(=O)(=O)C=2C=C1S(=O)(=O)N1CCCCC1 YYTHOTQYXLODRO-UHFFFAOYSA-N 0.000 description 1
PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229940126657 Compound 17 Drugs 0.000 description 1
229940126639 Compound 33 Drugs 0.000 description 1
229940127007 Compound 39 Drugs 0.000 description 1
ZGUNAGUHMKGQNY-SSDOTTSWSA-N D-alpha-phenylglycine Chemical compound OC(=O)[C@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-SSDOTTSWSA-N 0.000 description 1
RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
241001365121 Hampa Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
229920004011 Macrolon® Polymers 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
WAGRKJVEJDGFGK-UHFFFAOYSA-N N,N,3-trimethyl-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide N,N,3-trimethyl-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide Chemical compound CC=1NS(C2=C(N1)C=CC(=C2)S(N(C)C)(=O)=O)(=O)=O.CC2NS(C1=C(N2)C=CC(=C1)S(N(C)C)(=O)=O)(=O)=O WAGRKJVEJDGFGK-UHFFFAOYSA-N 0.000 description 1
239000012580 N-2 Supplement Substances 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
DHDVUBIKJYPMBN-UHFFFAOYSA-N NC1=C(C=C(C=C1Br)Br)S(=O)(=O)N.C1(CCCCC1)C1NS(C2=C(N1)C(=CC(=C2)Br)Br)(=O)=O Chemical compound NC1=C(C=C(C=C1Br)Br)S(=O)(=O)N.C1(CCCCC1)C1NS(C2=C(N1)C(=CC(=C2)Br)Br)(=O)=O DHDVUBIKJYPMBN-UHFFFAOYSA-N 0.000 description 1
SYEMFFQBDNKGNK-UHFFFAOYSA-N NC1=C(C=CC=C1)S(=O)(=O)N.CN(S(=O)(=O)C1=CC2=C(N3C(=NS2(=O)=O)CCC3)C=C1)C Chemical compound NC1=C(C=CC=C1)S(=O)(=O)N.CN(S(=O)(=O)C1=CC2=C(N3C(=NS2(=O)=O)CCC3)C=C1)C SYEMFFQBDNKGNK-UHFFFAOYSA-N 0.000 description 1
OUJWSNHYRLTBSC-UHFFFAOYSA-N NC1=C(C=CC=C1)S(=O)(=O)N.CN(S(=O)(=O)C1=CC2=C(N3C(NS2(=O)=O)CCC3)C=C1)C Chemical compound NC1=C(C=CC=C1)S(=O)(=O)N.CN(S(=O)(=O)C1=CC2=C(N3C(NS2(=O)=O)CCC3)C=C1)C OUJWSNHYRLTBSC-UHFFFAOYSA-N 0.000 description 1
RSINDCWMUJSGFO-UHFFFAOYSA-N NC1=C(C=CC=C1)S(=O)(=O)N.CNS(=O)(=O)C1=CC2=C(N3C(NS2(=O)=O)CCC3)C=C1 Chemical compound NC1=C(C=CC=C1)S(=O)(=O)N.CNS(=O)(=O)C1=CC2=C(N3C(NS2(=O)=O)CCC3)C=C1 RSINDCWMUJSGFO-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
QHNXAGGYRXNQQC-UHFFFAOYSA-N Nc1ccccc1S(N)(=O)=O.CNS(=O)(=O)c1ccc2N3CCCC3=NS(=O)(=O)c2c1 Chemical compound Nc1ccccc1S(N)(=O)=O.CNS(=O)(=O)c1ccc2N3CCCC3=NS(=O)(=O)c2c1 QHNXAGGYRXNQQC-UHFFFAOYSA-N 0.000 description 1
RSXXMZLNIUMWNA-UHFFFAOYSA-N Nc1ccccc1S(N)(=O)=O.O=S(=O)(N1CCCCC1)c1ccc2NC(Cc3ccccc3)NS(=O)(=O)c2c1 Chemical compound Nc1ccccc1S(N)(=O)=O.O=S(=O)(N1CCCCC1)c1ccc2NC(Cc3ccccc3)NS(=O)(=O)c2c1 RSXXMZLNIUMWNA-UHFFFAOYSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
MRESPPBBIYSBKP-UHFFFAOYSA-N OC=1C=C(C=CC1)B(O)O.C1(CCCCC1)C1NS(C2=C(N1)C=CC(=C2)C2=CC(=CC=C2)O)(=O)=O Chemical compound OC=1C=C(C=CC1)B(O)O.C1(CCCCC1)C1NS(C2=C(N1)C=CC(=C2)C2=CC(=CC=C2)O)(=O)=O MRESPPBBIYSBKP-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical class [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
238000006069 Suzuki reaction reaction Methods 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229940091179 aconitate Drugs 0.000 description 1
229940091181 aconitic acid Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
230000036982 action potential Effects 0.000 description 1
125000004442 acylamino group Chemical group 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
150000007854 aminals Chemical class 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000012223 aqueous fraction Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
150000001502 aryl halides Chemical class 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
230000006399 behavior Effects 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
150000007658 benzothiadiazines Chemical class 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
WPOWLMALYNHBSG-UHFFFAOYSA-N bicyclo[2.2.1]hept-2-ene-3-carbaldehyde Chemical compound C1CC2C(C=O)=CC1C2 WPOWLMALYNHBSG-UHFFFAOYSA-N 0.000 description 1
UAQYREPFSVCDHT-UHFFFAOYSA-N bicyclo[2.2.1]heptane-3-carbaldehyde Chemical compound C1CC2C(C=O)CC1C2 UAQYREPFSVCDHT-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
125000001626 borono group Chemical group [H]OB([*])O[H] 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
125000006425 chlorocyclopropyl group Chemical group 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
XAEXSWVTEJHRMH-UHFFFAOYSA-N chloropyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=C(Cl)S1 XAEXSWVTEJHRMH-UHFFFAOYSA-N 0.000 description 1
229950005434 chloropyrilene Drugs 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
229940114081 cinnamate Drugs 0.000 description 1
GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000007278 cognition impairment Effects 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
229940126142 compound 16 Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
229940126086 compound 21 Drugs 0.000 description 1
229940126208 compound 22 Drugs 0.000 description 1
229940125833 compound 23 Drugs 0.000 description 1
229940125961 compound 24 Drugs 0.000 description 1
229940125846 compound 25 Drugs 0.000 description 1
229940125851 compound 27 Drugs 0.000 description 1
229940127204 compound 29 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
229940125877 compound 31 Drugs 0.000 description 1
229940125878 compound 36 Drugs 0.000 description 1
229940127573 compound 38 Drugs 0.000 description 1
229940126540 compound 41 Drugs 0.000 description 1
229940125936 compound 42 Drugs 0.000 description 1
229940125844 compound 46 Drugs 0.000 description 1
229940127271 compound 49 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
229940126545 compound 53 Drugs 0.000 description 1
229940127113 compound 57 Drugs 0.000 description 1
229940125900 compound 59 Drugs 0.000 description 1
229940126179 compound 72 Drugs 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000007428 craniotomy Methods 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
VELDYOPRLMJFIK-UHFFFAOYSA-N cyclopentanecarbaldehyde Chemical compound O=CC1CCCC1 VELDYOPRLMJFIK-UHFFFAOYSA-N 0.000 description 1
FIROOANTCDHWIN-UHFFFAOYSA-N cyclopentanecarbaldehyde 3-cyclopentyl-7-piperidin-1-ylsulfonyl-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine 1,1-dioxide Chemical compound C1(CCCC1)C=O.C1(CCCC1)C1NS(C2=C(N1)C=CC(=C2)S(=O)(=O)N2CCCCC2)(=O)=O FIROOANTCDHWIN-UHFFFAOYSA-N 0.000 description 1
WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
239000005343 cylinder glass Substances 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000006196 deacetylation Effects 0.000 description 1
238000003381 deacetylation reaction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
BTZWIZOMVVQOAZ-UHFFFAOYSA-L dichlorosilver Chemical compound Cl[Ag]Cl BTZWIZOMVVQOAZ-UHFFFAOYSA-L 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001035 drying Methods 0.000 description 1
229950005627 embonate Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
125000006351 ethylthiomethyl group Chemical group [H]C([H])([H])C([H])([H])SC([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000002461 excitatory amino acid Effects 0.000 description 1
239000003257 excitatory amino acid Substances 0.000 description 1
238000004880 explosion Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
125000006419 fluorocyclopropyl group Chemical group 0.000 description 1
239000006260 foam Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000003371 gabaergic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
125000005347 halocycloalkyl group Chemical group 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
125000006428 iodocyclopropyl group Chemical group 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001793 isothiazol-3-yl group Chemical group [H]C1=C([H])C(*)=NS1 0.000 description 1
125000004500 isothiazol-4-yl group Chemical group S1N=CC(=C1)* 0.000 description 1
125000004501 isothiazol-5-yl group Chemical group S1N=CC=C1* 0.000 description 1
125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 1
125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
JMZFEHDNIAQMNB-UHFFFAOYSA-N m-aminophenylboronic acid Chemical compound NC1=CC=CC(B(O)O)=C1 JMZFEHDNIAQMNB-UHFFFAOYSA-N 0.000 description 1
NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007074 memory dysfunction Effects 0.000 description 1
230000006993 memory improvement Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
HDIWBVUJWJJWAJ-UHFFFAOYSA-N n,n-dimethyl-5,5-dioxo-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine-7-sulfonamide Chemical compound N1S(=O)(=O)C2=CC(S(=O)(=O)N(C)C)=CC=C2N2CCCC21 HDIWBVUJWJJWAJ-UHFFFAOYSA-N 0.000 description 1
YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
YFLMJEUEGWZATF-UHFFFAOYSA-N n-(2-sulfamoylphenyl)acetamide Chemical compound CC(=O)NC1=CC=CC=C1S(N)(=O)=O YFLMJEUEGWZATF-UHFFFAOYSA-N 0.000 description 1
QGEBGEQVEBJMIL-UHFFFAOYSA-N n-(3-cyclohexyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-7-yl)methanesulfonamide Chemical compound N1S(=O)(=O)C2=CC(NS(=O)(=O)C)=CC=C2N=C1C1CCCCC1 QGEBGEQVEBJMIL-UHFFFAOYSA-N 0.000 description 1
ZXYSRVSPDUSHBX-UHFFFAOYSA-N n-(4-bromophenyl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=C(Br)C=C1 ZXYSRVSPDUSHBX-UHFFFAOYSA-N 0.000 description 1
YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
STYLLEODAYZRAS-UHFFFAOYSA-N n-cyclohexyl-3-methyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C2S(=O)(=O)NC(C)=NC2=CC=C1S(=O)(=O)NC1CCCCC1 STYLLEODAYZRAS-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
230000001423 neocortical effect Effects 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000008906 neuronal response Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002664 nootropic agent Substances 0.000 description 1
UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
125000005593 norbornanyl group Chemical group 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 1
125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
210000003455 parietal bone Anatomy 0.000 description 1
239000006072 paste Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940100595 phenylacetaldehyde Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920000166 polytrimethylene carbonate Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
239000013630 prepared media Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
HJSRRUNWOFLQRG-UHFFFAOYSA-N propanedioic acid Chemical compound OC(=O)CC(O)=O.OC(=O)CC(O)=O HJSRRUNWOFLQRG-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
229940075554 sorbate Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009782 synaptic response Effects 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
230000024587 synaptic transmission, glutamatergic Effects 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
239000012085 test solution Substances 0.000 description 1
150000004685 tetrahydrates Chemical class 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
GYUURHMITDQTRU-UHFFFAOYSA-N tributyl(pyridin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CC=N1 GYUURHMITDQTRU-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
YFNKIDBQEZZDLK-UHFFFAOYSA-N triglyme Chemical compound COCCOCCOCCOC YFNKIDBQEZZDLK-UHFFFAOYSA-N 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1
SJZNRVUBNAJWQA-UHFFFAOYSA-N trimethyl(2h-triazol-4-yl)silane Chemical compound C[Si](C)(C)C1=CNN=N1 SJZNRVUBNAJWQA-UHFFFAOYSA-N 0.000 description 1
HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
- C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
- C07D285/28—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

SK1189-2000A 1998-02-18 1999-02-18 Zlúčeniny a ich použitie ako pozitívnych modulátorov ampa receptora SK11892000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK22698		1998-02-18
PCT/DK1999/000070 WO1999042456A2 (en)	1998-02-18	1999-02-18	Novel compounds and their use as positive ampa receptor modulators

Publications (1)

Publication Number	Publication Date
SK11892000A3 true SK11892000A3 (sk)	2001-02-12

Family

ID=8091151

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1189-2000A SK11892000A3 (sk)	1998-02-18	1999-02-18	Zlúčeniny a ich použitie ako pozitívnych modulátorov ampa receptora

Country Status (17)

Country	Link
EP (1)	EP1071426A2 (zh)
JP (1)	JP2002504481A (zh)
CN (1)	CN1293665A (zh)
AU (1)	AU751384B2 (zh)
CA (1)	CA2320354A1 (zh)
EE (1)	EE200000468A (zh)
HU (1)	HUP0101280A3 (zh)
IL (1)	IL137720A0 (zh)
IS (1)	IS5581A (zh)
NO (1)	NO20004121L (zh)
NZ (1)	NZ506251A (zh)
PL (1)	PL342843A1 (zh)
RU (1)	RU2214405C2 (zh)
SK (1)	SK11892000A3 (zh)
TR (1)	TR200002427T2 (zh)
WO (1)	WO1999042456A2 (zh)
ZA (1)	ZA991301B (zh)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7671200B2 (en)	1999-10-27	2010-03-02	Cytokinetics, Inc.	Quinazolinone KSP inhibitors
DE10004572A1 (de)	2000-02-02	2001-08-09	Boehringer Ingelheim Pharma	Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
FR2812291B1 (fr) *	2000-07-28	2002-12-13	Adir	Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1314351A (zh) *	2001-03-22	2001-09-26	刘志红	喹唑啉酮合成方法及具有抗癌作用的一类喹唑啉酮化合物
TWI232863B (en)	2001-06-11	2005-05-21	Akzo Nobel Nv	Benzoxazepine derivatives
SK287583B6 (sk) *	2001-06-14	2011-03-04	N.V. Organon	(Pyrido/tieno)-[f]-oxazepin-5-ónové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
MXPA04003297A (es)	2001-10-10	2004-07-23	Neurosearch As	Derivados novedosos de benzotiacina su preparacion y uso.
SK2292004A3 (en) *	2001-11-26	2004-09-08	Cortex Pharma Inc	Carbonyl benzoxazine compounds for enhancement of glutamatergic synaptic responses
FR2833956B1 (fr) *	2001-12-21	2004-01-30	Servier Lab	Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2833950B1 (fr) *	2001-12-21	2005-12-16	Servier Lab	Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2833955B1 (fr)	2001-12-21	2004-01-30	Servier Lab	Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2854634B1 (fr) *	2003-05-05	2005-07-08	Servier Lab	Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2856064B1 (fr) *	2003-06-13	2005-08-19	Servier Lab	Nouveaux derives de benzothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2856065B1 (fr) *	2003-06-13	2005-08-19	Servier Lab	Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
RU2006102869A (ru)	2003-07-02	2007-08-10	Ф.Хоффманн-Ля Рош Аг (Ch)	Ариламинозамещенные хиназолиноновые соединения
EP1667643A4 (en)	2003-08-28	2008-03-05	Nitromed Inc	NITROSIS AND NITROSYL CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
US7244843B2 (en)	2003-10-07	2007-07-17	Bristol-Myers Squibb Company	Modulators of serotonin receptors
FR2865474B1 (fr) *	2004-01-26	2008-06-13	Servier Lab	Nouveaux derives de benzothiazines fluorees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2877338B1 (fr)	2004-11-03	2007-01-26	Servier Lab	Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2877342B1 (fr)	2004-11-03	2007-01-26	Servier Lab	Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2879201B1 (fr) *	2004-12-10	2007-02-16	Servier Lab	Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2319461T3 (es)	2005-02-10	2009-05-07	Bristol-Myers Squibb Company	Dihidroquinazolinonas como moduladores de 5ht.
CA2597460A1 (en)	2005-02-24	2006-08-31	Nitromed, Inc.	Nitric oxide enhancing diuretic compounds, compositions and methods of use
GB0507298D0 (en) *	2005-04-11	2005-05-18	Novartis Ag	Organic compounds
TW200800959A (en)	2005-06-10	2008-01-01	Wyeth Corp	Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
WO2008085506A1 (en)	2007-01-03	2008-07-17	Cortex Pharmaceuticals, Inc.	3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
CL2008000119A1 (es)	2007-01-16	2008-05-16	Wyeth Corp	Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
TW200911768A (en)	2007-05-17	2009-03-16	Cortex Pharma Inc	Di-substituted amides for enhancing glutamatergic synaptic responses
BRPI0823262A2 (pt)	2007-08-10	2013-09-24	Cortex Pharma Inc	mÉtodo de tratamento de depressço respiratària e uso de um composto na fabricaÇço de um medicamento para o tratamento de depressço respiratària
US8168632B2 (en)	2007-08-10	2012-05-01	Cortex Pharmaceuticals, Inc.	Bicyclic amide derivatives for the treatment of respiratory disorders
FR2933698A1 (fr)	2008-07-09	2010-01-15	Servier Lab	Nouveaux derives de benzothiadiazines cycloalkylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2943342B1 (fr) *	2009-03-20	2011-03-04	Servier Lab	Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU2010276537B2 (en)	2009-07-27	2015-04-16	Gilead Sciences, Inc.	Fused heterocyclic compounds as ion channel modulators
FR2955106B1 (fr)	2010-01-08	2011-12-23	Servier Lab	Nouveaux derives de benzothiadiazines cyclopropylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2955107B1 (fr) *	2010-01-08	2012-03-02	Servier Lab	Nouveaux derives thiochromanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR101911560B1 (ko)	2010-07-02	2018-10-24	길리애드 사이언시즈, 인코포레이티드	이온 채널 조정제로서의 융합된 헤테로시클릭 화합물
CN102958919A (zh) *	2010-07-02	2013-03-06	霍夫曼-拉罗奇有限公司	新的四氢喹啉衍生物
FR2964969B1 (fr)	2010-09-16	2012-08-24	Servier Lab	Nouveaux derives dihydrobenzoxathiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IT1402905B1 (it) *	2010-11-29	2013-09-27	Univ Degli Studi Modena E Reggio Emilia	Derivati di 1,2,4-benzotiadiazin 1,1-diossido, loro preparazione e loro impiego come modulatori allosterici del recettore ampa.
CA2834164A1 (en)	2011-05-10	2012-11-15	Gilead Sciences, Inc.	Fused benzoxazinones as ion channel modulators
TWI549944B (zh)	2011-07-01	2016-09-21	吉李德科學股份有限公司	作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (zh)	2011-07-01	2018-04-28
CN102977054A (zh) *	2012-12-12	2013-03-20	中国药科大学	一类选择性α2A受体激动剂的治疗阿尔茨海默病用途
JO3316B1 (ar)	2013-05-30	2019-03-13	Lilly Co Eli	مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
UA118562C2 (uk)	2013-05-30	2019-02-11	Ідорсія Фармасьютікалз Лтд	Модулятори рецептора cxcr7
CN103275016B (zh) *	2013-06-04	2015-03-11	温州医科大学附属第二医院	一种2-取代喹唑啉化合物的合成方法
BR112015031249A2 (pt)	2013-06-13	2017-07-25	Veroscience Llc	método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica
CN103319381B (zh) *	2013-06-14	2014-08-27	湖州康企药业有限公司	一种高纯度精磺胺的制备方法
CN103772296B (zh) *	2013-12-19	2015-06-17	安徽师范大学	一种喹唑啉衍生物的合成方法
CA2963447A1 (en)	2014-12-01	2016-06-09	Actelion Pharmaceuticals Ltd	Cxcr7 receptor modulators
CN105294599B (zh) *	2015-09-17	2017-09-22	三峡大学	一种噻二嗪类化合物及其不对称的合成方法
CN106946920A (zh) *	2017-04-05	2017-07-14	泰力特医药（湖北）有限公司	一种4‑氨基苯硼酸衍生物的制备方法
WO2020223255A1 (en)	2019-04-29	2020-11-05	Solent Therapeutics, Llc	3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
WO2020253860A1 (zh) *	2019-06-21	2020-12-24	江苏豪森药业集团有限公司	芳基磷氧化物类衍生物抑制剂、其制备方法和应用
RU2726456C1 (ru) *	2019-10-02	2020-07-14	Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар")	Ингибитор вируса гепатита В (ВГВ)
CN111100042B (zh) *	2019-11-18	2022-05-31	苏州诚和医药化学有限公司	一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法
CN111018750B (zh) *	2019-12-19	2022-05-27	苏州诚和医药化学有限公司	一种2,3-二甲氧基-5-磺酰胺基苯甲酸的制备新方法
WO2024115797A2 (en) *	2022-12-30	2024-06-06	Aexon Labs. Inc.	Dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives and use thereof as orexin receptors agonists for treating or preventing neurological diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL296964A (zh) *
US3275625A (en) *		1966-09-27		Derivatives of
FR1217929A (fr) *	1958-03-03	1960-05-06	Ciba Geigy	Procédé de préparation du 1,1-dioxyde de la 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine et de ses sels
GB863474A (en) *	1958-08-13	1961-03-22	Knud Abildgaard	Benzothiadiazine derivatives and their preparation
DE1125938B (de) *	1960-02-12	1962-03-22	Thomae Gmbh Dr K	Verfahren zur Herstellung von 7-Sulfamyl-3, 4-dihydro-1, 2, 4-benzothiadiazin-1, 1-dioxyden
GB946864A (en) *	1960-05-06	1964-01-15	Knud Abildgaard	Method for the production of 3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxides
US3419552A (en) *	1961-04-12	1968-12-31	Lilly Co Eli	Preparation of substituted dihydrobenzothiadiazine-1,1-dioxides
CH475269A (de) *	1962-04-19	1969-07-15	Hans Voigt Chem Pharm Fabrik D	Verfahren zur Herstellung von 7-Sulfonamido-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
US3351595A (en) *	1962-12-07	1967-11-07	Ciba Geigy Corp	Derivatives of 3, 4-dihydro-2h-1, 2, 4-benzothiadiazine-1, 1-dioxide
US3311620A (en) *	1963-05-31	1967-03-28	Stanley C Bell	Fused ring benzothiadiazines
US3277086A (en) *	1964-07-07	1966-10-04	American Home Prod	1, 2, 4-benzothiadiazine 1, 1-dioxides having a heterocyclic ring fused to the "b" face thereof
US4184039A (en) *	1977-12-01	1980-01-15	Paul Finkelstein	Benzothiadiazine 1, 1-dioxides
AU3957093A (en) *	1992-04-15	1993-11-18	Rhone-Poulenc Rorer S.A.	3,4-dihydro-2H-1,2,4-benzothiadiazine-1,1-dioxide-3-carboxyl ic acid derivatives, preparation thereof and drugs containing same
US5488049A (en) *	1993-12-10	1996-01-30	Fidia - Georgetown Institute For The Neuro-Sciences	Method of treating learning and memory disorders using benzothiadiazide derivatives as nootropic agents
FR2722502B1 (fr) *	1994-07-12	1996-08-23	Adir	Nouveau derive de benzothiadiazine, son procede depreparation et les compositions pharmaceutiques qui le contiennent
WO1997026884A1 (en) *	1996-01-29	1997-07-31	The Regents Of The University Of California	Method for treating sexual dysfunctions
AU4345297A (en) *	1996-09-17	1998-04-14	Regents Of The University Of California, The	Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor

1999
- 1999-02-18 PL PL99342843A patent/PL342843A1/xx unknown
- 1999-02-18 IL IL13772099A patent/IL137720A0/xx unknown
- 1999-02-18 RU RU2000121882/04A patent/RU2214405C2/ru not_active IP Right Cessation
- 1999-02-18 SK SK1189-2000A patent/SK11892000A3/sk unknown
- 1999-02-18 WO PCT/DK1999/000070 patent/WO1999042456A2/en not_active Application Discontinuation
- 1999-02-18 HU HU0101280A patent/HUP0101280A3/hu unknown
- 1999-02-18 NZ NZ506251A patent/NZ506251A/xx unknown
- 1999-02-18 EE EEP200000468A patent/EE200000468A/xx unknown
- 1999-02-18 AU AU25123/99A patent/AU751384B2/en not_active Ceased
- 1999-02-18 CN CN99804196A patent/CN1293665A/zh active Pending
- 1999-02-18 JP JP2000532408A patent/JP2002504481A/ja not_active Withdrawn
- 1999-02-18 ZA ZA9901301A patent/ZA991301B/xx unknown
- 1999-02-18 EP EP99904730A patent/EP1071426A2/en not_active Withdrawn
- 1999-02-18 TR TR2000/02427T patent/TR200002427T2/xx unknown
- 1999-02-18 CA CA002320354A patent/CA2320354A1/en not_active Abandoned
2000
- 2000-08-04 IS IS5581A patent/IS5581A/is unknown
- 2000-08-17 NO NO20004121A patent/NO20004121L/no unknown

Also Published As

Publication number	Publication date
AU2512399A (en)	1999-09-06
NO20004121L (no)	2000-10-17
PL342843A1 (en)	2001-07-16
IS5581A (is)	2000-08-04
JP2002504481A (ja)	2002-02-12
RU2214405C2 (ru)	2003-10-20
WO1999042456A3 (en)	1999-10-07
EP1071426A2 (en)	2001-01-31
EE200000468A (et)	2002-04-15
HUP0101280A3 (en)	2003-02-28
CA2320354A1 (en)	1999-08-26
TR200002427T2 (tr)	2001-01-22
NZ506251A (en)	2003-01-31
WO1999042456A2 (en)	1999-08-26
HUP0101280A2 (hu)	2001-10-28
ZA991301B (en)	1999-09-13
AU751384B2 (en)	2002-08-15
NO20004121D0 (no)	2000-08-17
CN1293665A (zh)	2001-05-02
IL137720A0 (en)	2001-10-31

Publication	Publication Date	Title
SK11892000A3 (sk)	2001-02-12	Zlúčeniny a ich použitie ako pozitívnych modulátorov ampa receptora
US6943159B1 (en)	2005-09-13	Compounds and their use as positive AMPA receptor modulators
EP2590950B1 (en)	2014-10-15	N-cyclyl-3-(cyclylcarbonylaminomethyl)benzamide derivatives as rho kinase inhibitors
EP1551834B1 (en)	2010-08-25	Substituted quinazolinone compounds
US8686002B2 (en)	2014-04-01	Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
US20080161297A1 (en)	2008-07-03	Rho kinase inhibitors
TW200843770A (en)	2008-11-16	RHO kinase inhibitors
US20040224964A1 (en)	2004-11-11	Heterocyclic derivatives as CRF antagonists
BR0113331B1 (pt)	2017-11-14	Phenylalanin derivatives or its parmaceutically acceptable salts, integrine alpha 4 antagonist, therapeutic agent or preventive agent for inflammatory diseases, and pharmaceutical composition
DK158838B (da)	1990-07-23	Quinazolinderivater, en fremgangsmaade til fremstilling deraf, farmaceutiske praeparater indeholdende derivater samt anvendelse af derivaterne til fremstilling af medikamenter
WO2003011872A1 (en)	2003-02-13	Platelet adp receptor inhibitors
WO2005032488A2 (en)	2005-04-14	2,4-dioxo-3-quinazolinylaryl sulfonylureas
SK96494A3 (en)	1995-07-11	Piperazine and piperidine derivatives, and their use as antipsychotic
AU2004272104A1 (en)	2005-03-24	Fused ring heterocycles as potassium channel modulators
AU2009312032A1 (en)	2010-05-14	Carbamate compound or salt thereof
JP2009179616A (ja)	2009-08-13	３−ナフチルピラゾール化合物
MXPA06005736A (es)	2006-12-14	Compuestos de quinazolinona con bioacumulacion reducida.
SK67794A3 (en)	1995-02-08	Imidazopyridines
AU2007323888A1 (en)	2008-05-29	Allosteric modulators of the A1 adenosine receptor
CA2473362A1 (en)	2003-07-24	Substituted alkyl uracils and the use thereof
CZ20002896A3 (cs)	2001-01-17	Nové sloučeniny a jejich použití jako pozitivních modulátorů AMPA receptoru
JP2006290791A (ja)	2006-10-26	アゾール置換スルホニルベンゼン誘導体
MXPA00008128A (en)	2001-07-09	Novel compounds and their use as positive ampa receptor modulators